These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32534561)

  • 1. Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
    Wu H; Xiang X; Li D; Shen S; Li X
    Curr Pharm Des; 2020; 26(46):5988-5997. PubMed ID: 32534561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
    Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
    Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy assessment of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention by data mining and machine-learning decision tree approaches.
    Xue Y; Hu Z; Jing Y; Wu H; Li X; Wang J; Seybert A; Xie X; Lv Q
    J Clin Pharm Ther; 2020 Oct; 45(5):1076-1086. PubMed ID: 32627223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.
    Zhuo X; Zhuo B; Ouyang S; Niu P; Xiao M
    BMC Pharmacol Toxicol; 2018 Sep; 19(1):54. PubMed ID: 30176938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
    Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
    J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness and Safety of Ticagrelor Versus Clopidogrel for Elderly Chinese Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Retrospective Cohort Study.
    Xu S; Liang Y; Chen Y; Gao H; Tan Z; Wang Q; Liu Y; Zhu B; Tao F; Wang Q; Zhao S; Yang L; Zhang Y; Wang Z; Han P; Chen Y; Zhang A; Li C; Lian K
    Drugs Aging; 2022 Sep; 39(9):695-703. PubMed ID: 35995912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of clopidogrel and ticagrelor under NT-proBNP in hospitalized ST-elevation acute coronary syndrome patients on percutaneous coronary intervention: CCC-ACS Project Analysis.
    Zhao X; Ai G; Qiu M; Wang X; Zhang L; Yang X; Liu Y; Xu P; Zhang J; Gu C; Zhou M; Hao Y; Zhao D; Han Y;
    Int J Cardiol; 2020 Jul; 310():1-8. PubMed ID: 32307186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis.
    Guo Y; Ge P; Li Z; Xiao J; Xie L
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):533-546. PubMed ID: 37530990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ma Y; Zhong PY; Shang YS; Bai N; Niu Y; Wang ZL
    J Cardiovasc Pharmacol; 2022 May; 79(5):632-640. PubMed ID: 35091511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Turgeon RD; Koshman SL; Youngson E; Har B; Wilton SB; James MT; Graham MM
    JAMA Intern Med; 2020 Mar; 180(3):420-428. PubMed ID: 31930361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome.
    Li D; Sun Y; Ye X; Li L; Chen Y; Wang D
    Adv Ther; 2022 Jan; 39(1):754-766. PubMed ID: 34904209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention.
    Wang C; Zheng W; Shaqdan A; Wang C; Qin X; Zhao X; Wang X; Yuan L; Nie S; Liu R
    Platelets; 2020; 31(3):337-343. PubMed ID: 31043110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
    Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A
    Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang HY; Li Y; Xu XM; Li J; Han YL
    Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention.
    Li Y; Li J; Qiu M; Ma S; Na K; Li X; Qi Z; Chen S; Li Y; Han Y
    Catheter Cardiovasc Interv; 2022 May; 99 Suppl 1():1395-1402. PubMed ID: 35032148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Clopidogrel Versus Ticagrelor for Stabilized Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention: Results From a Real-World Registry in China.
    Peng W; Zhang Y; Li X; Lin Y
    J Cardiovasc Pharmacol; 2023 Feb; 81(2):134-140. PubMed ID: 36410041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice.
    Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A
    J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.